{
  "meta": {
    "publisher": "Mass Tort Marketing Agency",
    "dataset": "Cost Per Signed Retainer (CPR) Benchmark",
    "release": "2026-q1",
    "quarter": "Q1 2026",
    "temporalCoverage": "2026-01-01/2026-03-31",
    "dataAsOf": "2026-03-31",
    "published": "2026-04-24",
    "lastReviewed": "2026-06-10",
    "methodologyVersion": "1.0",
    "methodologyUrl": "https://www.masstortmarketingagency.com/benchmarks/methodology",
    "canonicalUrl": "https://www.masstortmarketingagency.com/benchmarks/ozempic",
    "verification": {
      "status": "unverified",
      "reviewer": null,
      "statement": "No third party has reviewed this methodology or the underlying data. Mass Tort Marketing Agency sells the leads these figures price."
    },
    "vendorDisclosure": "Mass Tort Marketing Agency sells the mass tort leads these figures price. The panel is the agency's own client base and the underlying performance data is self-reported by those firms.",
    "sourcesDisclosure": "Benchmark ranges are drawn from the panel performance data cross-referenced against published industry surveys and practitioner-disclosed benchmarks. Those sources are not named in the published methodology, and how they enter the calculation is not specified.",
    "license": {
      "name": "CC BY 4.0",
      "url": "https://creativecommons.org/licenses/by/4.0/",
      "attribution": "Mass Tort Marketing Agency CPR Benchmark, https://www.masstortmarketingagency.com/benchmarks/"
    },
    "nullConvention": "A null value is never a zero and never an estimate. Every null is paired with an adjacent *Reason field stating why the value is unavailable.",
    "snapshotUrl": "https://www.masstortmarketingagency.com/benchmarks/data/2026-q1.json"
  },
  "tort": {
    "slug": "ozempic",
    "name": "Ozempic (GLP-1 agonist gastroparesis)",
    "status": "Active",
    "cpr": {
      "low": 4200,
      "median": null,
      "medianUnavailableReason": "Per-tort medians are not published. The dataset carries the interquartile low and high bounds for each tort; only the national median is published as a point value.",
      "high": 6100,
      "currency": "USD"
    },
    "signedRatePct": {
      "low": 7,
      "high": 11
    },
    "qualificationTier": "High",
    "sampleSize": null,
    "sampleSizeUnavailableReason": "Per-tort sample sizes are not broken out in the published dataset. The panel total (140 firms, $180M of annual mass tort lead spend across 16 active tort categories) is published at the panel level only, so the number of firms and the spend basis behind any single row cannot be stated.",
    "confidenceInterval": null,
    "confidenceIntervalUnavailableReason": "Not computable from the published dataset. Benchmarks are published as trimmed interquartile ranges, and the per-observation values a confidence interval requires are not retained in the published figures.",
    "falloffPct": {
      "low": 28,
      "high": 28
    },
    "falloffUnavailableReason": null,
    "falloffNote": "Stated as a single current figure (28%), not a range.",
    "rowUpdated": "2026-04-24",
    "rowUpdatedNote": "Rows are refreshed as a complete set each release, so every row carries the release publication date rather than an independent per-row date.",
    "qualificationCriteria": "Ozempic or other GLP-1 agonist use plus a documented gastroparesis diagnosis — not simple nausea or GI discomfort.",
    "statusAndAcquisition": "Active, the newest high-volume tort in the benchmark, and criteria are still evolving. The low end of the signed-rate band reflects that many self-reporting claimants have GI symptoms that do not rise to gastroparesis on clinical evaluation. MDL leadership has telegraphed further narrowing in 2026, likely requiring gastric emptying scintigraphy documented within a defined window of GLP-1 use. Firms anticipating that narrowing pre-screen for motility testing and refuse to sign without it: signed volume drops 30-40% but falloff falls to 12-15%, improving effective CPR 18-22%.",
    "relatedTorts": [
      "suboxone",
      "depo-provera",
      "oxbryta"
    ],
    "canonicalUrl": "https://www.masstortmarketingagency.com/benchmarks/ozempic",
    "quarter": "Q1 2026"
  },
  "series": {
    "low": [
      {
        "release": "2024-q4",
        "label": "Q4 2024",
        "dataAsOf": "2024-12-31",
        "value": null,
        "valueReason": "No per-tort breakdown for Q4 2024 is held in the dataset. Only the national median is held for that quarter, which is why the per-tort trend series begins at Q1 2026."
      },
      {
        "release": "2026-q1",
        "label": "Q1 2026",
        "dataAsOf": "2026-03-31",
        "value": 4200,
        "valueReason": null
      }
    ],
    "high": [
      {
        "release": "2024-q4",
        "label": "Q4 2024",
        "dataAsOf": "2024-12-31",
        "value": null,
        "valueReason": "No per-tort breakdown for Q4 2024 is held in the dataset. Only the national median is held for that quarter, which is why the per-tort trend series begins at Q1 2026."
      },
      {
        "release": "2026-q1",
        "label": "Q1 2026",
        "dataAsOf": "2026-03-31",
        "value": 6100,
        "valueReason": null
      }
    ]
  },
  "annotations": []
}